Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > RCH-01 alternative

<< Previous

Bullboard Posts

Next >>

Comment by bluemoons20on Dec 25, 2023 9:41pm

105 Views

Post# 35800203

RE:RE:RCH-01 alternative

Sorry if I mis-spoke. However, here is one big differnece. One product is on the market being sold (whether effective or not) and our product is a long way from that position. Unfortunately , I have been in a lot of these types of stocks where the story behind the POTENTIAL product is good but somehow it never gets traction and the dilution keeps rolling with long term shareholders left holding the bag.

Happy NewYear to all as well as a lot of luck for 2024.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario